Celemics Inc
Celemics, Inc. designs, manufactures, and distributes sequencing kits in South Korea. The company offers whole exome sequencing panels; NGS target enrichment panels; customized and ready-to-use enrichment panels; and modular accessories, including library preparation kits, double standard Cdna synthesis, hybridization enhancer, celan-up and streptavidin beads, CeleNM beads, and polymerase. It als… Read more
Celemics Inc (331920) - Net Assets
Latest net assets as of September 2025: ₩23.94 Billion KRW
Based on the latest financial reports, Celemics Inc (331920) has net assets worth ₩23.94 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩25.88 Billion) and total liabilities (₩1.94 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩23.94 Billion |
| % of Total Assets | 92.51% |
| Annual Growth Rate | N/A |
| 5-Year Change | -7.4% |
| 10-Year Change | N/A |
| Growth Volatility | 189.42 |
Celemics Inc - Net Assets Trend (2017–2024)
This chart illustrates how Celemics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Celemics Inc (2017–2024)
The table below shows the annual net assets of Celemics Inc from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩27.18 Billion | +71.16% |
| 2023-12-31 | ₩15.88 Billion | -14.56% |
| 2022-12-31 | ₩18.59 Billion | -20.51% |
| 2021-12-31 | ₩23.39 Billion | -20.34% |
| 2020-12-31 | ₩29.36 Billion | +469.44% |
| 2019-12-31 | ₩5.16 Billion | +117.07% |
| 2018-12-31 | ₩-30.20 Billion | -183.24% |
| 2017-12-31 | ₩-10.66 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Celemics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2816077664000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩4.08 Billion | 15.02% |
| Other Components | ₩63.36 Billion | 233.07% |
| Total Equity | ₩27.18 Billion | 100.00% |
Celemics Inc Competitors by Market Cap
The table below lists competitors of Celemics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Silvano Fashion Group AS
WAR:SFG
|
$31.75 Million |
|
Mieco Chipboard Bhd
KLSE:5001
|
$31.77 Million |
|
US Global Investors Inc
NASDAQ:GROW
|
$31.78 Million |
|
IMT Co., Ltd.
KQ:451220
|
$31.79 Million |
|
Ballarpur Industries Limited
NSE:BALLARPUR
|
$31.74 Million |
|
Silkeborg IF Invest A/S
CO:SIF
|
$31.74 Million |
|
Kinatico Ltd
AU:KYP
|
$31.73 Million |
|
Garanti Faktoring AS
IS:GARFA
|
$31.73 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Celemics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 15,882,347,020 to 27,184,154,530, a change of 11,301,807,510 (71.2%).
- Net income of 12,266,477,640 contributed positively to equity growth.
- Other factors decreased equity by 964,670,130.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩12.27 Billion | +45.12% |
| Other Changes | ₩-964.67 Million | -3.55% |
| Total Change | ₩- | 71.16% |
Book Value vs Market Value Analysis
This analysis compares Celemics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.06x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ₩-1654.68 | ₩6850.00 | x |
| 2018-12-31 | ₩-4686.69 | ₩6850.00 | x |
| 2019-12-31 | ₩799.99 | ₩6850.00 | x |
| 2020-12-31 | ₩3621.84 | ₩6850.00 | x |
| 2021-12-31 | ₩2864.50 | ₩6850.00 | x |
| 2022-12-31 | ₩2276.93 | ₩6850.00 | x |
| 2023-12-31 | ₩1945.38 | ₩6850.00 | x |
| 2024-12-31 | ₩3329.70 | ₩6850.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Celemics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 45.12%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 182.56%
- • Asset Turnover: 0.23x
- • Equity Multiplier: 1.08x
- Recent ROE (45.12%) is above the historical average (-10.91%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.00% | -83.42% | 0.38x | 0.00x | ₩-655.10 Million |
| 2018 | 0.00% | -774.69% | 0.29x | 0.00x | ₩-16.53 Billion |
| 2019 | -43.75% | -43.87% | 0.71x | 1.40x | ₩-2.77 Billion |
| 2020 | -16.05% | -89.50% | 0.17x | 1.04x | ₩-7.65 Billion |
| 2021 | -22.40% | -64.79% | 0.30x | 1.15x | ₩-7.58 Billion |
| 2022 | -25.80% | -54.95% | 0.39x | 1.19x | ₩-6.66 Billion |
| 2023 | -24.40% | -58.92% | 0.36x | 1.14x | ₩-5.46 Billion |
| 2024 | 45.12% | 182.56% | 0.23x | 1.08x | ₩9.55 Billion |
Industry Comparison
This section compares Celemics Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $98,321,642,752
- Average return on equity (ROE) among peers: 7.10%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Celemics Inc (331920) | ₩23.94 Billion | 0.00% | 0.08x | $31.75 Million |
| Shinhung (004080) | $87.31 Billion | 3.50% | 0.52x | $10.80 Million |
| Osang Healthcare Co.,Ltd (036220) | $199.86 Billion | 20.34% | 0.25x | $37.44 Million |
| HansBiomed Corporation (042520) | $43.16 Billion | 11.38% | 0.21x | $246.58 Million |
| JVM Co. Ltd (054950) | $98.83 Billion | 10.23% | 0.72x | $117.37 Million |
| Huvitz Co. Ltd (065510) | $51.68 Billion | 16.97% | 0.32x | $43.64 Million |
| Vieworks Co. Ltd (100120) | $188.04 Billion | 17.80% | 0.28x | $101.54 Million |
| Corentec Co Ltd (104540) | $48.30 Billion | -3.04% | 0.46x | $40.80 Million |
| Hironic Co. Ltd (149980) | $40.72 Billion | 7.13% | 0.15x | $23.71 Million |
| Laseroptek Co., Ltd. (199550) | $-3.94 Billion | 0.00% | 0.00x | $21.68 Million |
| Humasis Co. Ltd (205470) | $229.26 Billion | -13.28% | 0.45x | $48.97 Million |